Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (1491)	1/6/2006 9:49:38 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AFFX opened on a downgap. Was trading down 8% in the premarket after it announced yesterday at 6PM that it will miss its revenue target for the 4thQ by $15M.<g> It blamed delays on completing genotyping processes & low instrument sales.AFFX had already lowered its guidance for the 4thQ in October.With this new cut on the projected revenues, it seems that the 4thQ numbers will be about 1M below the 2004 results.<g> Its CEO said that the company is having "growing pains", but that its DNA analysis has grown to 90M in 2005 and it has record orders for 2006. On the other hand, Perlegen announced today that it started a collaboration with DNA to study the genetics of cancer.<g> This dip on AFFX may turn to be a chance to get some more of its shares before the planned Perlegen's IPO.<g> bigcharts.marketwatch.com AFFX opened at 42.90 but is now up to 43.65 It seems the dip will not test the Dec.20 L of 42.22 much less the Sept.28 L of 40.03 <g> Bernard ra